Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
← catalyst calendarNCT06575192 · readout ≤ 1,654 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
264estimated
Sites
23
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-05 | actual | When the study began enrolling |
| Primary completion | Feb 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Reconstruction
Intervention
- Device: ARTIA Reconstructive Tissue Matrix
Primary outcomes
what the primary-completion date above is the date OFOccurrence of at Least One Major Complication related to Breast Reconstruction After Stage 1
measured Month 18
Number of Participants with Adverse Events (AEs)
measured Up to Approximately 36 Months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed